Numerous bacterial pathogens, particularly those that colonize fast-flow areas in the bladder and gastrointestinal tract, require motility to establish infection and spread beyond the initially colonized tissue. Vibrio cholerae strains of serogroups O1 and O139, the causative agents of the diarrheal illness cholera, express a single polar flagellum powered by sodium motive force and require motility to colonize and spread along the small intestine. Therefore, motility may be an attractive target for small molecules that can prevent and/or block the infective process. In this study, we describe a high-throughput screening (HTS) assay to identify small molecules that selectively inhibit bacterial motility. The HTS assay was used to screen an ϳ8,000-compound structurally diverse chemical library for inhibitors of V. cholerae motility. The screen identified a group of quinazoline-2,4-diamino analogs that completely suppressed motility without affecting the growth rate in broth. A further study on the effects of one analog, designated Q24DA, showed that it induces a flagellated but nonmotile (Mot ؊ ) phenotype and is specific for the Na ؉ -driven flagellar motor of pathogenic Vibrio species. A mutation conferring phenamil-resistant motility did not eliminate inhibition of motility by Q24DA. Q24DA diminished the expression of cholera toxin and toxin-coregulated pilus as well as biofilm formation and fluid secretion in the rabbit ileal loop model. Furthermore, treatment of V. cholerae with Q24DA impacted additional phenotypes linked to Na ؉ bioenergetics, such as the function of the primary Na ؉ pump, Nqr, and susceptibility to fluoroquinolones. The above results clearly show that the described HTS assay is capable of identifying small molecules that specifically block bacterial motility. New inhibitors such as Q24DA may be instrumental in probing the molecular architecture of the Na ؉ -driven polar flagellar motor and in studying the role of motility in the expression of other virulence factors.Cholera is an acute waterborne diarrheal disease caused by Vibrio cholerae strains of serogroups O1 and O139. This Gramnegative pathogen continues to be a major public health concern in areas of endemicity in South Asia and Africa, with an estimated 5 million cases and more than 100,000 deaths per year. Cases of severe cholera are commonly treated with antibiotics to diminish the duration of its life-threatening clinical symptoms. In this regard, the emergence of multipleantibiotic-resistant V. cholerae O1 and O139 strains has been recognized as a major concern (12,43,45,49). The availability of novel prophylactic measures and/or adjunctive therapies could contribute to diminishing the burden of cholera and antibiotic resistance.V. cholerae strains that cause epidemic cholera exhibit three major virulence traits: (i) production of cholera toxin (CT), (ii) expression of the toxin-coregulated pilus (TCP), and (iii) expression of a single, fast-rotating sheathed polar flagellum driven by sodium motive force (SMF) (34). CT is an AD...